Biology changes before symptoms begin.
SYNC-PREVENT™ is a Clinical Status Monitoring platform built around eleven detection layers — laboratory biomarkers, FDA-cleared in-office diagnostics, and AI-assembled clinical context — for patients 50 and older living with two or more chronic conditions, built to close the gap standard care leaves open.
This is not an RPM dashboard. It watches the whole patient.
SYNC-PREVENT™ stands for Proactive Risk Evaluation, Vital Early Notification Tracking. The name describes the job: find the disease while it's still quiet — before the symptom, before the admission, before the point where reversing it gets hard and expensive. Remote monitoring and chronic care management are part of the machinery. They are not the idea.
For patients 50 and older, eleven detection layers — lab work, in-office device diagnostics, AI interpretation, and behavioral follow-through — feed one continuously refreshed view of where each patient's physiology is heading.
The starting point was the American Heart Association's cardiovascular risk model. That model takes a snapshot: traditional risk factors, one moment in time. Synchronize Health built SYNC-PREVENT™ to do what a snapshot can't — follow real physiologic change as it happens, across organ systems, month after month. The platform runs directly and through exclusive regional licensees, including our subsidiary BridgeCare Louisiana.
Most first hospitalizations arrive somewhere around 65 to 70. The fifteen years before that are where the disease builds — quietly. That's the window this platform is pointed at.
Every clinical decision belongs to the treating physician. SYNC-PREVENT™ gathers, interprets, and carries out the work between visits — it never writes an order and never directs care. Each alert and escalation exists for one reason: so the physician sees an earlier, fuller picture and decides with better information than standard care gives them.
Six jobs. Each one measurable.
The design targets specific clinical and operational outcomes for physicians, patients, payers, and the teams around them.
Surface cardiovascular, renal, metabolic, neurologic, and endocrine problems while they're still pre-symptomatic — territory that score-based and symptom-driven models never reach.
Go past the AHA snapshot with biomarker trends over time, device data, kidney-adjusted reads, and analysis that crosses organ systems.
Each core layer sits on an existing CMS billing pathway and plugs into RPM and CCM workflows — advanced monitoring without unfunded services.
Structured screening for CKD, diabetes, hypertension, heart failure, and diabetic eye disease closes the care gaps that quality scores and value-based contracts grade you on.
Early alerts and structured escalation give the physician a chance to act before the acute event — not a report about it afterward.
TEFCA/Carequality connectivity keeps primary care, specialists, and hospitals reading from the same current chart, so transitions stop dropping information.
Eleven ways of looking. One picture of the patient.
Every layer watches for one category of physiologic trouble. No value is read alone — results are trended over time, corrected for kidney function where it matters, and checked against the other layers by AI reasoning engines before the physician ever sees them.
Layers 1–8 run on reimbursable, CMS-aligned lab and device testing. Layers 9–11 are handled separately, with the clinical context they require.
Finds arterial disease while it's still forming — plaque activity, vascular inflammation, and the inherited lipid risk a standard LDL-C misses.
Catches heart failure and kidney decline while they're still subclinical — including the PTH-driven cardiac pathway that quietly raises HFpEF risk in women past menopause.
Spots insulin resistance years before glucose goes abnormal. Insulin-dependent patients in higher care tiers get a Dexcom G7 feeding this layer continuously.
Watches for fatty liver disease and fibrosis — a silent cardiovascular driver the AHA model never looks at. Velacur elastography confirms when labs raise the question.
Tracks the low-grade inflammatory burden that feeds atherosclerosis, diabetes, and renal disease — plus the nutritional depletion that precedes deterioration.
Flags anemia and impaired oxygen transport — under-recognized accelerants of cardiac and cognitive decline — and reads lymphocyte count as a frailty and infection-vulnerability signal.
Device-based testing for dysautonomia — an early warning for sudden cardiac events and diabetic neuropathy that standard vitals never show.
Finds peripheral artery disease before limb ischemia develops — and the early microvascular signals of diabetic foot ulcer risk.
Blood-based markers of silent brain injury and cognitive decline risk. Ordered only on physician determination — and always read against kidney function, which independently elevates all three markers.
Motion-based gait analysis that sees the fall coming before it happens — stride variability, balance, and instability patterns that predate any frailty diagnosis.
Replaces "seems sharp today" with measured memory, attention, processing speed, and executive function — trended visit over visit, corroborating Layer 9's blood markers.
Kidney function changes what every number means.
A biomarker reading in a patient with CKD is not the same reading in a patient with healthy kidneys. Reduced clearance inflates inflammatory markers, vascular injury signals, and neurodegenerative markers alike — and a system that ignores that will misclassify patients, refer them too early, escalate therapy they don't need, and bill for it.
So renal physiology isn't a downstream diagnosis here — it's wired into the interpretation itself. Renal-adjusted trend analysis separates stable clearance-related elevation from true pathologic progression, and the physician receives the difference: a signal instead of a false alarm.
FDA-cleared devices, run in your clinic, results in minutes.
Each device operates on-site under physician supervision, bills through existing CMS pathways, and feeds its findings straight into the matching detection layer — no workflow disruption, no added staff burden.
Reads left ventricular end-diastolic pressure without a catheter — surfacing early heart failure physiology, including HFpEF, that no physical exam can find.
One retinal image, a referral decision in about a minute — the HEDIS diabetic eye exam gap closed without sending the patient anywhere.
Automated ankle- and toe-brachial index. Peripheral artery disease and limb ischemia risk, found before they limit the patient.
HRV, sudomotor function, and autonomic balance — early diabetic neuropathy and cardiovascular instability, caught in a routine visit.
Quantifies hepatic stiffness and steatosis for MASLD/MASH staging — ordered when FIB-4 or Layer 4 labs raise the question.
AI-assisted detection of AFib, murmurs, and early heart failure signals during the ordinary exam — every visit becomes a screening.
Continuous glycemic trends for insulin-dependent patients in higher care tiers — a moving picture between visits instead of a single fingerstick.
Plantar temperature asymmetry flags diabetic foot ulcer risk two to four weeks before anything is visible — ahead of ulceration, infection, or amputation.
OSA severity, respiratory instability, and desaturation — the sleep apnea quietly feeding AFib, HFpEF, hypertension, and CKD progression.
A raw lab value doesn't tell a physician anything. Context does.
Meaning lives in the surroundings — the medication list, the comorbidities, the trend line, the way findings in one organ system echo in another. Language-model reasoning engines assemble that context and hand it to the physician in usable form. They cite evidence, not opinions. They never make the decision.
Reads the whole patient — labs, vitals, medications, comorbidities, EHR notes, RPM data — and returns cross-organ reasoning the physician can act on. Refreshed every 30–90 days with CCM/RPM cycles.
Watches biomarkers, device data, and history in real time, reclassifying risk as new data lands — short-term instability prediction, care-gap flags, escalation scoring. Full reassessment every 90 days per CMS.
Computes fibrosis risk from age, AST, ALT, and platelets the patient already gave — no extra draw — placed against metabolic, cardiac, and renal context. Updated every 6–12 months.
RPM and CCM carry the findings. They aren't the foundation.
Monitoring and chronic care management are how a finding becomes a phone call, an adherence check, a medication reconciliation — the follow-through that turns an insight into an outcome a payer can measure.
The people making calls understand the conditions, the medications, and the escalation pathways. What reaches the physician is filtered and clinically relevant — no noise.
Escalation is structured so a status change lands with the right person, at the right urgency, at the right time — not in a shared inbox on Monday.
Medication adherence is verified — and reconciled against TEFCA/Carequality data — to cut the medication-driven readmissions and care gaps.
Reports arrive aligned with CMS requirements and ready for signature — the administrative burden goes down, not sideways onto your staff.
A missed reading is a clinical variable, not a nag-reminder trigger. Engagement gaps get structured behavioral intervention under the COM-B framework.
TEFCA/Carequality connectivity gives clinicians the complete patient — not just device readings — with HIPAA-grade data security throughout.
Admissions, discharges, ED visits, abnormal labs, device-detected deterioration — meaningful changes reach the whole care team as they happen, through TEFCA/Carequality connectivity and event-based alerts. When everyone reads the same current chart, transition gaps close, duplicate tests stop, and conflicting treatment decisions become visible before they cause harm.
Detect. Interpret. Act.
FDA-cleared devices and trended biomarkers pick up physiologic change while it's still silent — cardiac, renal, metabolic, neurologic.
Reasoning engines cross-check findings across all eleven layers, correct for renal physiology, and assemble the context a physician needs.
The treating physician — and no one else — decides. SYNC-PREVENT™ delivers the picture. It never delivers the decision.
SYNC-PREVENT™ doesn't watch one disease. It watches the whole trajectory of deterioration — before the symptom, before the hospitalization, before the outcome hardens.
This page describes the design of the SYNC-PREVENT™ clinical protocol and is informational only — not medical advice, a diagnosis, or a treatment recommendation. Testing, device use, referrals, and escalations happen solely at the treating physician's direction. Testing frequencies reflect protocol design and may differ per patient. SYNC-PREVENT™ is a trademark of Synchronize Health, LLC.
Close your blind spot.
Thirty minutes. We'll show you what you're missing between visits.
Talk to Our Team